SREBF1 and neoplasm: For example, Mehta et al. showed that PARP inhibitors can enhance both anti- and pro-tumor features of macrophages via glucose and lipid metabolic reprogramming, mediated by the sterol regulatory element-binding protein 1 (SREBP-1) pathway [27].